Lal S, Bhalla K K
Curr Med Res Opin. 1975;3(2):63-7. doi: 10.1185/03007997509113648.
Bromhexine, 16 mg. 3-times daily, was compared with placebo in a double-blind crossover trial in 41 out-patients with chronic bronchitis and irreversible airways obstruction, and who were considered to be in a steady state. Each treatment was given for 3 weeks with a week of placebo in between; in addition, all patients took oxytetracycline, 500 mg. twice daily, starting 1 week before the trial and continuing throughout the duration of it. All patients completed the trial but the results from 5 were excluded because during the first 3 weeks they developed an influenza-like illness accompanied by a decrease in FEV1,and peak expiratory flow rate. Results from the remaining 36 patients showed a statistically significant reduction in phlegm stickiness (p smaller than 0.05) as judged by the patient, and a significant improvement in overall clinical state (p smaller than 0.05) as judged by the physician during bromhexine treatment, but no significant change in symptoms like cough, chest tightness, ease of breathing or sputum volume, peak expiratory flow rate and FEV1 etc. Five patients reported 6 side-effects, 3 with bromhexine, 1 with placebo and 1 with both treatments.
在一项双盲交叉试验中,对41例患有慢性支气管炎且存在不可逆气道阻塞、被认为处于稳定状态的门诊患者,将16毫克溴己新每日3次的治疗方案与安慰剂进行了比较。每种治疗持续3周,中间间隔1周的安慰剂治疗;此外,所有患者从试验前1周开始每日2次服用500毫克土霉素,并在试验期间持续服用。所有患者均完成了试验,但有5例患者的结果被排除,因为在最初3周内他们患上了类似流感的疾病,同时第一秒用力呼气量(FEV1)和呼气峰值流速下降。其余36例患者的结果显示,在溴己新治疗期间,患者判断痰液黏稠度有统计学意义的降低(p小于0.05),医生判断总体临床状态有显著改善(p小于0.05),但咳嗽、胸闷、呼吸 ease of breathing(原文有误,推测为ease of breath)、痰量、呼气峰值流速和FEV1等症状无显著变化。5例患者报告了6例副作用,3例与溴己新有关,1例与安慰剂有关,1例与两种治疗均有关。